دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Novel aspects in the pathophysiology and diagnosis of glomerular diseases
Andreas Kronbichler, Ingeborg Bajema, Duvuru Geetha, Marcus Säemann
doi : 10.1136/ard-2022-222495
May 2023 - Volume 82 - 5
Immune deposits/complexes are detected in a multitude of tissues in autoimmune disorders, but no organ has attracted as much attention as the kidney. Several kidney diseases are characterised by the presence of specific configurations of such deposits, and many of them are under a ‘shared care’ between rheumatologists and nephrologists.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
Kevin L Winthrop, John D Isaacs, Philip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Tom W J Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
doi : 10.1136/ard-2022-223528
To detail the unmet clinical and scientific needs in the field of rheumatology. After a 2-year hiatus due to the SARS-CoV-2 pandemic, the 22nd annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties.
Tsai-Fan Yu: physician and researcher who established modern gout management
Nicola Dalbeth
doi : 10.1136/ard-2022-223597
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Benedicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindström, Johan Askling
doi : 10.1136/ard-2022-223762
Objective Longitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our objective was to assess and compare incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA), updating previous reports and including newer treatments including Janus Kinase inhibitors (JAKi).
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L Hyrich, Ann W Morgan, Anthony G Wilson, John D Isaacs, Darren Plant, Anne Barton
doi : 10.1136/ard-2022-222519
Objectives The inflammatory protein calprotectin (MRP8/14) has been identified as a promising biomarker of treatment response in rheumatoid arthritis (RA). Our aim was to test MRP8/14 as a biomarker of response to tumour necrosis factor (TNF)-inhibitors in the largest RA cohort to date and to compare with C-reactive protein (CRP).
Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis
Takuro Nii, Yuichi Maeda, Daisuke Motooka, Mariko Naito, Yuki Matsumoto, Takao Ogawa, Eri Oguro-Igashira, Toshihiro Kishikawa, Makoto Yamashita, Satoshi Koizumi, Takashi Kurakawa, Ryu Okumura, Hisako Kayama, Mari Murakami, Taiki Sakaguchi, Bhabatosh Das, Shota Nakamura, Yukinori Okada, Atsushi Kumanogoh, Kiyoshi Takeda
doi : 10.1136/ard-2022-222881
Objectives Prevotella copri is considered to be a contributing factor in rheumatoid arthritis (RA). However, in some non-Westernised countries, healthy individuals also harbour an abundance of P. copri in the intestine. This study investigated the pathogenicity of RA patient-derived P. copri (P. copri RA) compared with healthy control-derived P. copri (P. copri HC).
Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis
Liam J O'Neil, Christopher B Oliveira, Xinghao Wang, Mario Navarrete, Ana Barrera-Vargas, Javier Merayo-Chalico, Rwan Aljahdali, Eduardo Aguirre-Aguilar, Philip Carlucci, Mariana J Kaplan, Carmelo Carmona-Rivera
doi : 10.1136/ard-2022-223568
Objective Neutrophil infiltration into the synovial joint is a hallmark of rheumatoid arthritis (RA), a disease characterised by progressive bone erosion. However, the mechanisms by which neutrophils participate in bone destruction remain unclear.
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
Eric F Morand, Gabriel Abreu, Richard A Furie, Vera Golder, Raj Tummala
doi : 10.1136/ard-2022-222748
Objectives In patients with systemic lupus erythematosus (SLE), lupus low disease activity state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS attainment in anifrolumab-treated patients.
Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
Dionysis Nikolopoulos, Theodora Manolakou, Alexia Polissidis, Anastasia Filia, George Bertsias, Yassemi Koutmani, Dimitrios T Boumpas
doi : 10.1136/ard-2022-223506
Introduction Inflammatory mediators are detected in the cerebrospinal fluid of systemic lupus erythematosus patients with central nervous system involvement (NPSLE), yet the underlying cellular and molecular mechanisms leading to neuropsychiatric disease remain elusive.
Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
Meredyth G Ll Wilkinson, Dale Moulding, Thomas C R McDonnell, Michael Orford, Chris Wincup, Joanna Y J Ting, Georg W Otto, Restuadi Restuadi, Daniel Kelberman, Charalampia Papadopoulou, Sergi Castellano, Simon Eaton, Claire T Deakin, Elizabeth C Rosser, Lucy R Wedderburn
doi : 10.1136/ard-2022-223469
Objectives To define the host mechanisms contributing to the pathological interferon (IFN) type 1 signature in Juvenile dermatomyositis (JDM).
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
Burcu Ayoglu, Michele Donato, Daniel E Furst, Leslie J Crofford, Ellen Goldmuntz, Lynette Keyes-Elstein, Judith James, Susan Macwana, Maureen D Mayes, Peter McSweeney, Richard A Nash, Keith M Sullivan, Beverly Welch, Ashley Pinckney, Rong Mao, Lorinda Chung, Purvesh Khatri, Paul J Utz
doi : 10.1136/ard-2021-221926
Objectives Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesis that transplantation stabilises the autoantibody repertoire in patients with favourable clinical outcomes.
Risk factors for serious infections in ANCA-associated vasculitis
Balazs Odler, Regina Riedl, Philipp Gauckler, Jae Il Shin, Johannes Leierer, Peter A Merkel, William St. Clair, Fernando Fervenza, Duvuru Geetha, Paul Monach, David Jayne, Rona M Smith, Alexander Rosenkranz, Ulrich Specks, John H Stone, Andreas Kronbichler
doi : 10.1136/ard-2022-223401
Objectives Severe infections contribute to morbidity and mortality in antineutrophil cytoplasm antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial.
Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
Hui Gao, Shibo Liu, Yuanbang Mai, Yuying Wang, Xuewu Zhang, Shufen Zheng, Chenghua Luo, Cuiping Pan
doi : 10.1136/ard-2022-223736
Objectives Retroperitoneal fibrosis (RPF) is a rare autoimmune disease with fibrous tissue growth and inflammation in retroperitoneum. Its current treatments involve long-term uptake of glucocorticoids (e.g., prednisone) for controlling inflammation; however, side effects are common. We strived for an improved therapy for fibrosis remission while reducing side effects.
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Pedro M Machado, Martin Schäfer, Satveer K Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G S Saad, Christopher E M Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F Mateus, Emily Sirotich, Enrique R Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajão Martins, Helena Santos, Jonathan Dau, Jonathan N Barker, Jonathan Hausmann, Kimme L Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M Pinheiro, Marcos David Zelaya, MarÃa de los Ã�ngeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S Wallace, Zenas Z N Yiu, Jinoos Yazdany, Philip C Robinson, Catherine H Smith
doi : 10.1136/ard-2022-223499
Objectives To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Human-specific duplicate CHRFAM7A gene is associated with more severe osteoarthritis and amplifies pain behaviours
Alice Courties, Merissa Olmer, Kevin Myers, Phillip Ordoukhanian, Steven R Head, Padmaja Natarajan, Francis Berenbaum, Jérémie Sellam, Martin K Lotz
doi : 10.1136/ard-2022-223470
Objectives CHRFAM7A is a uniquely human fusion gene that functions as a dominant negative regulator of alpha 7 acetylcholine nicotinic receptor (α7nAChR) in vitro. This study determined the impact of CHRFAM7A on α7nAChR agonist responses, osteoarthritis (OA) severity and pain behaviours and investigated mechanisms.
Pyrogenic lower limbs
Eurydice Angeli, Alexander Ariel Padrón González, Diaddin Hamdan, Gabriel Pop, Géraldine Falgarone, Guilhem Bousquet
doi : 10.1136/ard-2022-222938
Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study
Le Zhang, Jun Li, Hanlin Yin, Dandan Chen, Yuan Li, Liyang Gu, Yakai Fu, Jie Chen, Zhiwei Chen, Shaoying Yang, Shuang Ye, Ting Li, Liangjing Lu
doi : 10.1136/ard-2022-223562
Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development
Bruno Raposo, Marcelo Afonso, Lena Israelsson, Heidi Wähämaa, Ragnhild Stålesen, Fredrik Wermeling, Aase Haj Hensvold, Caroline Grönwall, Bence Rethi, Lars Klareskog, Vivianne Malmström
doi : 10.1136/ard-2022-223417
Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Aaqib Zaffar Banday, Ankur Kumar Jindal, Surjit Singh
Response to: ‘Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’’ by Banday et al
Peter Nash, Josef S Smolen
Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults
Rui Gao, Lang Qin
Response to: ‘Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’’ by Gao and Qin
Maria G Tektonidou, Angela Tincani, Michael M Ward
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Pierre Charles
Response to: ’Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles
Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles
Josef S Smolen
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Selmi
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al
Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
Laurent Arnaud, Hervé Devilliers
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’ by Arnaud and Devilliers
Pedro M Machado, Martin Schäfer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F Mateus, Loreto Carmona, Kimme L Hyrich, Philip C Robinson, Jinoos Yazdany
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
Ben Mulhearn
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al
Martin Schäfer, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F Mateus, Laure Gossec, Philip C Robinson, Jinoos Yazdany, Pedro M Machado
Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France
Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, Jérome Drouin, Alain Weill, Rosemay Dray-Spira, Mahmoud Zureik
Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold?
Murugan Sudhakar, Pandiarajan Vignesh
Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis
Piero Ruscitti, Giorgio Sesti, Paola Cipriani, Roberto Gerli, Roberto Giacomelli
Response to: ‘Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis’’ by Ruscitti et al
Joshua F Baker, Bryant R England, Ted R Mikuls
Correspondence on ‘MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group
Zaid Jibri, Ummugulsum Gazel, Dilek Solmaz, Gizem Ayan, Jacob Karsh, Sibel Zehra Aydin, Marcos Sampaio
Response to: ‘Correspondence on ‘MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group’’ by Jibri et al
Walter P Maksymowych, Robert GW Lambert, Mikkel Østergaard, Xenofon Baraliakos
Correspondence on ‘Blood–brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment
Omer Nuri Pamuk, Sarfaraz Hasni
Response to: ‘Correspondence on ‘Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment’’ by Pamuk and Hasni
Lyna Kamintsky, Steven D Beyea, John D Fisk, Javeria A Hashmi, Antonina Omisade, Cynthia Calkin, Tim Bardouille, Chris Bowen, Maher Quraan, Arnold Mitnitski, Kara Matheson, Alon Friedman, John G Hanly
Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’
Samy Hakroush, Björn Tampe
Response to: ‘Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’’ by Hakroush and Tampe
Vincenzo L'Imperio, Gisella Vischini, Manuel Ferraro, Fabio Pagni
Correction: The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study
